Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.

Magnet Biomedicine builds on decades of molecular glue research from its scientific co-founder, Harvard University Professor Stuart Schreiber. The startup is developing drugs that take these glues beyond the biotech industry’s current focus on targeted protein degradation.

Avalon BioVentures unveiled new portfolio company Arialys Therapeutics. The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder.

The group of 10 startups in the accelerator have ambitions to improve early detection of lung cancer, eliminate contaminated needles, improve remote monitoring and provide new ways to treat head lice, among other goals.

By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.

Integral raked in $6.9 million in seed funding in this week. The San Francisco-based startup is developing technology that seeks to speed up the process of exchanging sensitive health data while still maintaining robust privacy protection.

As the value-based care market gets more crowded, startups in this space will have to nail down the fundamentals in order to attract capital from investors, healthcare business expert Paul Campbell said during a virtual conference. He encouraged startups to be crystal clear about what their value proposition is for three main stakeholders — patients, providers and payers.

Luna — an at-home physical therapy provider — released a new study on the efficacy of its post-surgery rehabilitation program. The study, which was conducted by the startup, showed that the Luna Pathways program did a good job of reducing patients’ pain, increasing care plan adherence, and decreasing avoidable hospital readmissions and emergency department visits.

Regard — a startup selling an AI co-pilot that helps clinicians diagnose medical conditions — announced a new partnership to add to its technology’s capabilities. The company is teaming up with OpenAI to release new chatbot functionalities built on OpenAI’s large language model GPT-4.

Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company’s platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.

Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.

Epic announced that it will integrate Abridge’s clinical documentation tool into its EHR workflow. The startup’s generative AI tool listens to visits and creates a near-instant summary that adheres to physicians’ prototypical note structure.

Biotech startups raised $2.6 billion globally in the second quarter of this year, but that’s down nearly 46% compared to the same period last year, according to a report from Pitchbook. Capital is harder to find, and the report projects an uptick in M&A activity as companies run out of cash.

Suvida Healthcare — a startup providing primary care for Medicare-eligible Hispanic adults — is adopting Elation Health’s primary care-specific technology platform. The platform comprises an EHR, as well as software for patient engagement, telehealth and revenue cycle management. Suvida’s chief medical officer said Elation beat out the competition due to its focus on both primary care and value-based care.

Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.”

Daybreak Health — a startup that partners with school districts to provide children with virtual mental health services — recently closed a $13 million Series B funding round. The company has partnered with more than 60 public school districts since it began providing care in 2019.

Chicago-based Rush University System for Health recently struck a partnership with Cadence — the health system is beginning an RPM pilot using the startup’s technology platform and clinicians. Rush will enroll Medicare and Medicaid patients who have one or more of the following chronic conditions: hypertension, congestive heart failure and type 2 diabetes.

A new startup named Uptiv Health launched to make infusion care more accessible and enjoyable for patients. The company, which was built at Redesign Health, is launching its flagship infusion center later this month in the Detroit area.

HerMD recently raised $18 million in a Series A-1 funding round. The company offers in-person and virtual women’s healthcare that focuses on menopause and sexual health. It is using its new capital to open more brick-and-mortar women’s health centers across the country.

A Phase 2b-ready Cyclerion Therapeutics drug candidate for a rare mitochondrial disease gets new life under a new startup led by a familiar face. Tisento Therapeutics acquired the Cyclerion drug and is backed by a Series A round financing.

RapidAI recently closed a $75 million Series C funding round led by Vista Credit Partners. The company offers an AI platform that helps hospital care teams triage and treat stroke patients more quickly.

Nexo Therapeutics is developing cancer drugs that expand the scope of amino acids addressable by covalent chemistry. Versant Ventures founded the startup and led its Series A financing.

NorthShore University HealthSystem teamed up with Laguna Health in 2021 to study whether greater post-acute care support can improve patient recovery and reduce readmissions. The research partners recently released results of the study, which found that giving patients emotional and psychological support after their discharge hastens recovery, decreases costs and alleviates physician burnout.

Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent.

The at-home care field holds significant market potential. As the subsector continues to grow, some leaders of home healthcare startups are challenging misconceptions that some other industry stakeholders may still have, including the misbelief that at-home care is only for senior citizens and that this care model lacks scalability.

Tenpoint Therapeutics’ name refers to the time it takes for an image to hit the retina and be processed by the brain. The regenerative medicine startup is developing cell therapies it hopes restore that vision capability for patients with degenerative eye disorders.

Sonio recently gained $14 million in Series A funding. The Paris-based startup’s AI platform automates ultrasound reporting so that healthcare providers can conduct ultrasound exams with greater accuracy, speed and efficiency.

Septerna Therapeutics’ Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that’s leaving the market. Potential rival therapies are all injectables.

Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup’s medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company’s scan takes about 10 minutes and costs €250 (about $275).

A new cohort of startups has graduated from PharmStars, a digital health accelerator. This latest group focused on women’s health and health equity.